EZH2 and acute myeloid leukemia: However, in a series of 128 patients with AML and MDS treated with azacytidine, pretreatment NGS analysis with a myeloid gene panel (containing ASXL1, RUNX1, DNMT3A, IDH1, IDH2, TET2, TP53, NRAS, KRAS, EZH2, SF3B1 and SRSF2) did not reveal a prognostic significance of mutations in the tested genes.